NF1 loss in estrogen receptor-positive breast cancer induces osteoclast formation and immunosuppression to promote bone metastasis
- 29 May 2026
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 655, 218636
Abstract
No abstract availableKeywords
Funding Information
- Cancer Prevention and Research Institute of Texas (RP210027)
- Cancer Prevention and Research Institute of Texas (RP240432)
- U.S. Department of War
- Baylor College of Medicine
- National Institutes of Health (CA125123)
- National Institutes of Health (OD038251)
- National Institutes of Health (OD036336)
- National Institutes of Health (P50CA186784)
This publication has 53 references indexed in Scilit:
- Isoform‐specific functions of Ras in T‐cell development and differentiationEuropean Journal of Immunology, 2023
- The bone microenvironment invigorates metastatic seeds for further disseminationCell, 2021
- Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast CancerCancer Cell, 2020
- The Osteogenic Niche Promotes Early-Stage Bone Colonization of Disseminated Breast Cancer CellsCancer Cell, 2015
- Tumor-Induced Osteoclast miRNA Changes as Regulators and Biomarkers of Osteolytic Bone MetastasisCancer Cell, 2013
- Cryopreservation modulates the detection of regulatory T cell markersCytometry Part B: Clinical Cytometry, 2011
- The musculoskeletal phenotype of the RASopathiesAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2011
- Skeletal abnormalities in neurofibromatosis type 1: Approaches to therapeutic optionsAmerican Journal of Medical Genetics Part A, 2009
- The molecular understanding of osteoclast differentiationBone, 2007
- The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasisCancer and Metastasis Reviews, 2006